HARVEST

High Dose Oral Rifampicin to Improve Survival from Adult Tuberculous Meningitis (HARVEST) is a double-blinded randomized placebo-controlled multinational/multisite Phase III Trial, conducted in Uganda, Indonesia and South Africa. The CCBR serves as the data coordinating center and the Infectious Diseases Institute at Makerere University in Uganda serves as the clinical coordinating center. The primary objective is to study whether high dose oral rifampicin can improve 6-month survival for adults with tuberculous meningitis. Besides the parent trial, a PK substudy lead by researchers from the Department of Pharmacy at Radboud University Medical Centre in the Netherland aims to study the pharmacokinetic/pharmacodynamic mechanism of the study drugs. 

Funder:  National Institutes of Health, National Institute of Allergy and Infectious Diseases.